1. Mullen, GED, Aebig, JA, Dobrescu, G, et al. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine. 2007;25(29):5343-5347.
Google Scholar | Crossref | Medline2. Qian, F, Rausch, KM, Muratova, O, et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine. 2008;26(20):2521-2527.
Google Scholar | Crossref | Medline3. Hu, S, Chen, H, Ma, J, et al. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection. J Appl Microbiol. 2013;115(5):1203-1211.
Google Scholar | Crossref | Medline4. Scheiermann, J, Klinman, DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32(48):6377-6389.
Google Scholar | Crossref | Medline5. Gu, M, Hine, PM, James Jackson, W, Giri, L, Nabors, GS. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine. 2007;25(3):526-534.
Google Scholar | Crossref | Medline6. Savransky, V, Shearer, JD, Gainey, MR, et al. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate. Vaccine. 2017;35(37):4952-4959.
Google Scholar | Crossref | Medline7. Autumn Smiley, M, Sanford, DC, Triplett, CA, et al. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909. Vaccine. 2019;37(43):6356-6361.
Google Scholar | Crossref | Medline8. Shearer, JD, Henning, L, Sanford, DC, et al. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart. Vaccine. 2021;39(1):1-5.
Google Scholar | Crossref | Medline9. Klinman, DM . CPG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. Expet Rev Vaccine. 2006;5(3):365-369.
Google Scholar | Crossref | Medline10. Rynkiewicz, D, Rathkopf, M, Sim, I, et al. Marked enhancement of the immune response to BioThrax (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine. 2011;29(37):6313-6320.
Google Scholar | Crossref | Medline11. Hopkins, RJ, Daczkowski, NF, Kaptur, PE, et al. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of anthrax vaccine adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine. 2013;31(30):3051-3058.
Google Scholar | Crossref | Medline12. Hopkins, RJ, Kalsi, G, Montalvo-Lugo, VM, et al. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults. Vaccine. 2016;34(18):2096-2105.
Google Scholar | Crossref | Medline13. WHO Guidelines on Nonclinical Evaluation of Vaccines, Annex 1. WHO Technical Report Series, No. 927, 2005
Google Scholar14. Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines, Annex 2 WHO Technical Report Series, No. 987, 2014
Google Scholar15. Gad, SC . Regulatory Toxicology. 2nd ed. London and New York: Taylor and Francis Publisher; 2001.
Google Scholar | Crossref16. Ivins, BE, Ezzell, JW, Jemski, J, Hedlund, KW, Ristroph, JD, Leppla, SH. Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun. 1986;52:454-458.
Google Scholar | Crossref | Medline17. Mullen, GED, Giersing, BK, Ajose-Popoola, O, et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine. 2006;24(14):2497-2505.
Google Scholar | Crossref | Medline18. Draize, JH . Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics. Austin, TX: Editorial Committee of The Association of Food and Drug Officials of the United States, Bureau of Food and Drugs; 1959.
Google Scholar19. Food and Drug Administration, HHS . International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), 2008
Google Scholar20. Weingand, K, Brown, G, Hall, R, et al. Harmonization of animal clinical pathology testing in toxicity and safety studies. the joint scientific committee for international harmonization of clinical pathology testing. Fund Appl Toxicol. 1996;29(2):198-201.
Google Scholar | Crossref | Medline21. Bregman, CL, Adler, RR, Morton, DG, Regan, KS, Yano, BL, , Society of Toxicologic Pathology. Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the society of toxicologic pathology (STP). Toxicol Pathol. 2003;31(2):252-253.
Google Scholar | SAGE Journals | ISI22. Quinn, CP, Semenova, VA, Elie, CM, et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis. 2002;8(10):1103-1110.
Google Scholar | Crossref | Medline23. Li, H, Soroka, SD, Taylor, TH, et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods. 2008;333(1-2):89-106.
Google Scholar | Crossref | Medline24. Inagaki, K, Koga, H, Inoue, K, Suzuki, K, Suzuki, H. Spontaneous intraocular hemorrhage in rats during postnatal ocular development. Comp Med. 2014;64(1):34-43.
Google Scholar | Medline | ISI25. Heywood, R . Some clinical observations on the eyes of Sprague-Dawley rats. Lab Anim. 1973;7(1):19-27.
Google Scholar | SAGE Journals26. Savransky, V, Lacy, M, Ionin, B, Skiadopoulos, MH, Shearer, J. Repeat-dose toxicity study of a lyophilized recombinant protective antigen-based anthrax vaccine adjuvanted with CpG 7909. Int J Toxicol. 2019;38(3):163-172.
Google Scholar | SAGE Journals | ISI27. Zmarowski, A, Ballin, JD, Sharits, J, et al. Repeat dose toxicity study of the AV7909 anthrax vaccine candidate in juvenile rats. Int J Toxicol. 2020;39:443-451. doi:10.1177/1091581820941412.
Google Scholar | SAGE Journals | ISI28. Mylchreest, E, Smiley, MA, Ballin, JD, et al. Developmental and reproductive safety evaluation of AV7909 anthrax vaccine candidate in rats. Birth Defects Res. 2021;113(1):32-42.
Google Scholar | Crossref | Medline29. Bernau, M, Kremer-Rücker, PV, Kreuzer, LS, et al. Magnetic resonance imaging to detect local tissue reactions after vaccination in sheep in vivo. Vet Record Open. 2017;4(1):e000200.
Google Scholar | Crossref | Medline30. Cooper, CL, Davis, HL, Morris, ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004;24(6):693-701.
Google Scholar | Crossref | Medline31. Cooper, CL, Davis, HL, Angel, JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005;19(14):1473-1479.
Google Scholar | Crossref | Medline32. Cooper, CL, Davis, HL, Morris, ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22(23-24):3136-3143.
Google Scholar | Crossref | Medline33. Duncan, CJA, Sheehy, SH, Ewer, KJ, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One. 2011;6(7):e22271.
Google Scholar | Crossref | Medline34. Mullen, GED, Ellis, RD, Miura, K, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One. 2008;3(8):e2940.
Google Scholar | Crossref | Medline35. Traore, B, Koné, Y, Doumbo, S, et al. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine. 2009;27(52):7299-7303.
Google Scholar | Crossref | Medline36. Offersen, R, Melchjorsen, J, Paludan, SR, Østergaard, L, Tolstrup, M, Søgaard, OS. TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Hum Vaccines Immunother. 2012;8(8):1042-1047.
Google Scholar | Crossref | Medline37. Søgaard, OS, Lohse, N, Harboe, ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis. 2010;51(1):42-50.
Google Scholar | Crossref | Medline38. La Rosa, C, Longmate, J, Lacey, SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012;205(8):1294-1304.
Google Scholar | Crossref | Medline | ISI39. Baldrick, P . Dose site reactions and related findings after vaccine administration in safety studies. J Appl Toxicol. 2016;36(8):980-990.
Google Scholar | Crossref | Medline | ISI40. Segal, L, Morelle, D, Blee, M, et al. Local tolerance and systemic toxicity of single and repeated intramuscular administrations of two different formulations of the RTS,S malaria candidate vaccine in rabbits. Regul Toxicol Pharmacol. 2015;71(2):269-278.
Google Scholar | Crossref | Medline41. Zhou, Xb, Lu, Jj, Jiang, Ys, et al. A safety study of inactivated Enterovirus 71 vaccine. Hum Vaccines Immunother. 2013;9(7):1430-1437.
Google Scholar | Crossref | Medline42. Ondondo, B, Brennan, C, Nicosia, A, Crome, SJ, Hanke, T. Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. Vaccine. 2013;31(47):5594-5601.
Google Scholar | Crossref | Medline43. Krieg, AM, Efler, SM, Wittpoth, M, Al Adhami, MJ, Davis, HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004;27(6):460-471.
Google Scholar | Crossref | Medline44. Vicari, AP, Luu, R, Zhang, N, et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Canc Immunol Immunother. 2009;58(4):615-628.
Google Scholar | Crossref | Medline45. Tosi, I, Bureau, F, Farnir, F, Denoix, JM, Lekeux, P, Art, T. Effects of a P-class CpG-ODN administered by intramuscular injection on plasma cytokines and on white blood cells of healthy horses. Vet Immunol Immunopathol. 2018;201:57-61.
Google Scholar | Crossref | Medline46. Watkinson, A, Soliakov, A, Ganesan, A, et al. Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions. Clin Vaccine Immunol. 2013;20(11):1659-1668.
Google Scholar | Crossref | Medline